Skulberg, Arne Kristian
Tylleskar, Ida
Nilsen, Turid
Skarra, Sissel
Salvesen, Øyvind
Sand, Trond
Loftsson, Thorsteinn
Dale, Ola
Funding for this research was provided by:
the Liaison Committee for Education, Research and Innovation in Central Norway
Joint Research Committee between St. Olavs Hospital, Trondheim University Hospital and the Faculty of Medicine and Health Sciences, NTNU, Norway
Article History
Received: 23 December 2017
Accepted: 12 March 2018
First Online: 22 March 2018
Compliance with ethical standards
:
: Norwegian University of Science and Technology (NTNU) and its subsidiary Technology Transfer Office (TTO) have a licencing agreement with Den norske Eterfabrikk (DnE) regarding the naloxone formulation studied. DnE has sent an application for marketing authorization for a drug for human consumption. NTNU, TTO and Ola Dale (OD) have financial benefit from these contracts. OD has been engaged by DnE as Principle Investigator in a pharmacokinetic study of naloxone for which OD receives no personal honorarium. DnE has compensated OD for two travels from Trondheim to Oslo.Arne Kristian Skulberg (AKS) has signed a non-compete contract with DnE lasting the duration of his PhD program (estimated 2018). This does not limit AKS right to publish results and he receives no royalties or other financial benefits from DnE/NTNU. Other authors declare they have no conflicts of interest.